353 related articles for article (PubMed ID: 10098753)
21. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer.
Higashiyama M; Taki T; Ieki Y; Adachi M; Huang CL; Koh T; Kodama K; Doi O; Miyake M
Cancer Res; 1995 Dec; 55(24):6040-4. PubMed ID: 8521390
[TBL] [Abstract][Full Text] [Related]
22. Loss of KAI1 expression in gastric cancer.
Tsutsumi S; Shimura T; Morinaga N; Mochiki E; Asao T; Kuwano H
Hepatogastroenterology; 2005; 52(61):281-4. PubMed ID: 15783050
[TBL] [Abstract][Full Text] [Related]
23. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression.
Adachi M; Taki T; Konishi T; Huang CI; Higashiyama M; Miyake M
J Clin Oncol; 1998 Apr; 16(4):1397-406. PubMed ID: 9552043
[TBL] [Abstract][Full Text] [Related]
24. KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese.
Hu WL; Li YQ; He HX; Li QR; Tian Y; Lai RQ; Mei H
Asian J Androl; 2000 Sep; 2(3):221-4. PubMed ID: 11225981
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of CD151 gene expression in non-small cell lung cancer.
Tokuhara T; Hasegawa H; Hattori N; Ishida H; Taki T; Tachibana S; Sasaki S; Miyake M
Clin Cancer Res; 2001 Dec; 7(12):4109-14. PubMed ID: 11751509
[TBL] [Abstract][Full Text] [Related]
26. Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines.
White A; Lamb PW; Barrett JC
Oncogene; 1998 Jun; 16(24):3143-9. PubMed ID: 9671393
[TBL] [Abstract][Full Text] [Related]
27. KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ; Lu CH; Chiou LC
Clin Cancer Res; 2003 Apr; 9(4):1393-8. PubMed ID: 12684410
[TBL] [Abstract][Full Text] [Related]
28. The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activity.
Zhou B; Liu L; Reddivari M; Zhang XA
Cancer Res; 2004 Oct; 64(20):7455-63. PubMed ID: 15492270
[TBL] [Abstract][Full Text] [Related]
29. MRP-1/CD9 and KAI1/CD82 expression in normal and various cancer tissues.
Huang C; Taki T; Adachi M; Yagita M; Sawada S; Takabayashi A; Inufusa H; Yoshie O; Miyake M
Int J Oncol; 1997 Nov; 11(5):1045-51. PubMed ID: 21528303
[TBL] [Abstract][Full Text] [Related]
30. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer.
Sho M; Adachi M; Taki T; Hashida H; Konishi T; Huang CL; Ikeda N; Nakajima Y; Kanehiro H; Hisanaga M; Nakano H; Miyake M
Int J Cancer; 1998 Oct; 79(5):509-16. PubMed ID: 9761121
[TBL] [Abstract][Full Text] [Related]
31. Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82.
Kawasaki G; Yoshitomi I; Yanamoto S; Yamada S; Mizuno A; Umeda M
Anticancer Res; 2011 Oct; 31(10):3521-6. PubMed ID: 21965773
[TBL] [Abstract][Full Text] [Related]
32. KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma.
Guo XZ; Friess H; Di Mola FF; Heinicke JM; Abou-Shady M; Graber HU; Baer HU; Zimmermann A; Korc M; Büchler MW
Hepatology; 1998 Dec; 28(6):1481-8. PubMed ID: 9828210
[TBL] [Abstract][Full Text] [Related]
33. [Expression of KAI1, MRP-1, and FAK proteins in lung cancer detected by high-density tissue microarray].
Wang XY; Liu T; Zhu CZ; Li Y; Sun R; Sun CY; Wang AX
Ai Zheng; 2005 Sep; 24(9):1091-5. PubMed ID: 16159431
[TBL] [Abstract][Full Text] [Related]
34. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma.
Yu L; Zhou L; Wu S; Gong X; Feng Z; Ma L; Zhu B; Yao N; Wang D; Dong H
World J Surg Oncol; 2014 Apr; 12():118. PubMed ID: 24758564
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma.
Xu F; Zhong W; Li J; Shanshen Z; Cui J; Nesland JM; Suo Z
Anticancer Res; 2005; 25(4):2943-50. PubMed ID: 16080548
[TBL] [Abstract][Full Text] [Related]
37. CD9 expression in gastric cancer and its significance.
Hori H; Yano S; Koufuji K; Takeda J; Shirouzu K
J Surg Res; 2004 Apr; 117(2):208-15. PubMed ID: 15047125
[TBL] [Abstract][Full Text] [Related]
38. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis.
Higashiyama M; Kodama K; Yokouchi H; Takami K; Adachi M; Taki T; Ishiguro S; Nakamori S; Yoshie O; Miyake M
Cancer; 1998 Aug; 83(3):466-74. PubMed ID: 9690539
[TBL] [Abstract][Full Text] [Related]
39. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer.
Ow K; Delprado W; Fisher R; Barrett J; Yu Y; Jackson P; Russell PJ
J Pathol; 2000 May; 191(1):39-47. PubMed ID: 10767717
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of KAI1 metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer.
Schindl M; Birner P; Breitenecker G; Oberhuber G
Gynecol Oncol; 2001 Nov; 83(2):244-8. PubMed ID: 11606078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
